NASDAQ:ZVRA
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc.'s revenue grew 350.9% in fiscal 2025 to $106.5M while operating margin rose to −59.1%. Free cash flow was −$2.4M, −2.3% of revenue, and the diluted share count rose 23.8%.Summary generated from Zevra Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$106.5M
Revenue growth+350.9%
Revenue, 5-yr CAGR+51.6%
Gross marginn/a
Operating margin−59.1%
Net margin78.2%
ROIC−55.1%
Return on equity85.7%
Debt / equity0.40
Free cash flow−$2.4M
FCF margin−2.3%
Share count change+23.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 29 | 10 | 27 | 24 | 106 |
| Operating income | 8 | −43 | −50 | −87 | −63 |
| Net income | −9 | −27 | −46 | −106 | 83 |
| Free cash flow | 10 | −19 | −34 | −70 | −2 |
Recent filings
- 4Insider transaction report
Aug 17, 2026 - 4Insider transaction report
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - DEF 14AProxy statement
Apr 20, 2026